| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Renal/Genitourinary System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Renal/Genitourinary System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Renal/Genitourinary System |
Recent Updates
Recently added Catalysts
Vertex Pharmaceuticals Incorporated$485.39
-9.21 (-1.85%)
A 86Pipeline Score Fair Value Pharma · Commercial
Market Cap
110.28 B
EPS
17.01
P/E Ratio
25.76 $
Value Trade
671.68 M
SEC Financials
Q1 2026Dilution Risk
Revenue
2.99 B
R&D Expenses
961.60 M
Operating CF
1.43 B
Total Assets
26.48 B
Total Liabilities
7.12 B
Equity
19.36 B
D/E Ratio
12,345
-4.17 %
Week
-0.65 %
1 Month
-6.94 %
3 Month
2.69 %
6 Month
99.97 %
5 Year
9,556 %
All Time
Cash Data
Cash Position
7.25 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
1.43 M
52 Week Range
362.50 - 507.92
% held by Insiders
0.21 %
% held by Institutions
95.69 %
Enterprise Value
105.01 B
Total Shares
253.83 M
Short %
1.95 %
Float Shares
253.32 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vertex Pharmaceuticals Incorporated
458Total events
22Upcoming
195Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 22
Sep 2026
T1FDA Filing Accepted
FDA acceptance of BLA expected; expedited review with Priority Review Voucher
Dec 2026
T2Enrollment Complete
On track to complete enrollment in both Phase 3 studies by end of 2026
2026-H1
T1NDA Submission
Vertex plans to file for approval of Casgevy in children aged 5 to 11 in first half of 2026
2026-H1
T1BLA Submission
Vertex expects to complete rolling BLA submission for povetacicept in first half of 2026
2026-H1
T1NDA Submission
On track to submit for global regulatory approvals for ALYFTREK in children ages 2-5
2026-H1
T2Trial Completion
On track to complete dosing in proof-of-concept study in first half of 2026
Event history 436
Jul 6, 2026
▲EU MAA SubmissionPALSONIFYEx-US Regulatory
EMA approval of PALSONIFY (paltusotine) for acromegaly
acromegalysource ↗
Jul 6, 2026
◆Trial InitiationatumelnantTrial
Phase 1/2b trial in ADCS currently enrolling patients
ACTH-dependent Cushing's syndromesource ↗
Jul 6, 2026
◆Trial InitiationpaltusotineTrial
Phase 3 clinical development for carcinoid syndrome
carcinoid syndrome associated with neuroendocrine tumorssource ↗
Jul 1, 2026
▲FDA ApprovalCasgevyApprovedFDA Decision
US FDA approval for expanded use of CASGEVY in patients ages 2 years and older with sickle cell disease or transfusion-dependent beta thalassemia
sickle cell disease or transfusion-dependent beta thalassemiasource ↗
Jun 11, 2026
◆Oral PresentationCasgevyApprovedPresentation
First European presentation of data in children ages 5–11 at EHA Congress
sickle cell disease and beta thalassemiasource ↗
Jun 11, 2026
◆Other Regulator MilestoneCasgevyApprovedEx-US Regulatory
Additional global regulatory submissions announced
sickle cell disease and beta thalassemiasource ↗
Jun 10, 2026
◆Oral PresentationPresentation
Vertex to participate in Goldman Sachs 47th Annual Global Healthcare Conference
Jun 5, 2026
◆Oral PresentationALYFTREKApprovedPresentation
Vertex Presents New Data on ALYFTREK at European Cystic Fibrosis Conference
cystic fibrosissource ↗
Jun 1, 2026
●BLA SubmissionpovetaciceptRegulatory Filing
BLA submission for accelerated approval of Povetacicept in IgA Nephropathy
IgA Nephropathysource ↗
Drug Pipeline Intelligence
A86
Pipeline Score $57.8B
Pipeline ValueFair Value
Valuation Signal77
Drugs Scored1.8x
rNPV / MCap Top 98%
Large Pharma (rank 19 of 911)
Percentile RankVertex Pharmaceuticals Incorporated earns an A-grade pipeline score (86/100), with $57.8B risk-adjusted pipeline value, led by VX-880 in Diabetes Mellitus, Type 1 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VX-880 Monoclonal antibody | Diabetes Mellitus, Type 1 | Phase 3 | NCT04786262 | 61% | $15.8B | RECRUITING | 52 | STALLED | D (21) | Jun 30, 2030 | LOW_RISK | LOW Jun 30, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VX-993 | acute pain after bunionectomy surgery | Phase 2 | 2025-08-05 | missed the trial’s primary endpoint, failing to show a statistically significant improvement Read More | Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings Read More | |
VX-993 | acute pain after bunionectomy surgery | Phase 2 | 2025-08-05 | missed the trial’s primary endpoint, failing to show a statistically significant improvement Read More | Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings Read More | |
VX-993 | acute pain after bunionectomy surgery | Phase 2 | 2025-08-05 | missed the trial’s primary endpoint, failing to show a statistically significant improvement Read More | Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VRTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VRTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VRTX▼ -1.9%today
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
Vertex Pharmaceuticals is set to announce its financial results for the second quarter of 2026 on August 3rd. This announcement is part of the company's regular financial reporting schedule. Details regarding the performance and outlook will likely be discussed during the announcement.
Read more →VRTXVertex to Acquire Crinetics Pharmaceuticals
Vertex Pharmaceuticals has announced its intention to acquire Crinetics Pharmaceuticals. The acquisition aims to enhance Vertex's portfolio and capabilities in the biopharmaceutical sector. Further details regarding the financial aspects and strategic implications of the acquisition have yet to be disclosed.
Read more →VRTX▲ +6%on this newsshared move
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Vertex has received FDA approval for the expanded use of CASGEVY® in treating individuals aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia. This approval represents a significant milestone in providing effective treatment options for these conditions. The decision is expected to enhance patient care and outcomes.
Read more →VRTXVertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
Vertex Pharmaceuticals presented new data on CASGEVY® at the European Hematology Association Congress. This included the first European presentation of data in children aged 5-11. Additionally, the company announced further global regulatory submissions related to CASGEVY®.
Read more →VRTXVertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
Vertex Pharmaceuticals presented new data on ALYFTREK® at the European Cystic Fibrosis Conference. The details of the findings were not disclosed in the article. The presentation is expected to contribute to ongoing discussions about cystic fibrosis treatments.
Read more →VRTXVertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
Vertex Pharmaceuticals will participate in the Goldman Sachs 47th Annual Global Healthcare Conference scheduled for June 10. This event is a significant platform for the company to engage with investors and discuss its strategic initiatives. Further details about the participation are yet to be disclosed.
Read more →VRTXVertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
Vertex Pharmaceuticals announced that the U.S. FDA has accepted its Biologics License Application for Povetacicept, aimed at treating IgA Nephropathy. This acceptance is a crucial step towards potential accelerated approval, which may enhance patient access to this innovative therapy. The company is optimistic about the drug's prospects in addressing this condition.
Read more →VRTXLilly, J&J CEOs top pharma’s highest paid list—again
Eli Lilly's David Ricks and Johnson & Johnson's Joaquin Duato topped the list of highest-paid pharma CEOs in 2025, with Ricks earning $36.7 million. Lilly's revenue surged by 45%, while Duato's compensation rose to $32.6 million. Other notable mentions include AbbVie's Robert Michael and Novartis's Vas Narasimhan, both exceeding $30 million in pay. Vertex's CEO Kewalramani and Merck's Davis faced slight decreases in their compensation packages.
Read more →VRTXVertex to Participate in Upcoming May 2026 Investor Conferences
Vertex Pharmaceuticals announced its participation in two upcoming investor conferences in May 2026. The company is known for its innovative therapies for serious diseases and has a strong clinical pipeline. Vertex has been recognized as a top employer, reflecting its commitment to workplace excellence.
Read more →VRTXVertex to Participate in Upcoming May Investor Conferences
Vertex Pharmaceuticals is set to participate in several investor conferences in May. The details regarding the specific conferences and the topics to be discussed have not been disclosed. This participation may provide insights into the company's future plans and developments.
Read more →VRTXVertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
Vertex Pharmaceuticals has secured a reimbursement agreement in Germany for its gene-edited therapy CASGEVY® (exagamglogene autotemcel). This agreement allows eligible patients aged 12 and older with severe sickle cell disease or transfusion-dependent beta thalassemia to access this innovative one-time treatment. This marks a significant advancement in treatment options available in Germany.
Read more →VRTXVertex’s quiet Q1 is calm before potentially ‘iconic’ renal evolution
Vertex Pharmaceuticals reported a steady Q1 2026, primarily driven by cystic fibrosis revenues. Analysts view this stability as a precursor to significant developments, particularly with povetacicept, which has shown promising Phase 3 data in treating IgA nephropathy. The company aims to establish a strong renal franchise, potentially rivaling its cystic fibrosis business.
Read more →VRTXDocument Vertex Reports First Quarter 2026 Financial Results - Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 - - Povetacicept program continues rapid advancement Completed rolling BLA subm
Vertex Pharmaceuticals reported strong Q1 2026 financial results with total revenue reaching $2.99 billion, an 8% increase from the previous year. The company highlighted advancements in the Povetacicept program, including the completion of a rolling BLA submission for accelerated approval in IgA nephropathy. Vertex also emphasized ongoing progress in its cystic fibrosis and sickle cell disease portfolios, including notable revenue contributions from its recently launched therapies. The firm reiterated its financial guidance for the full year, anticipating continued growth across its diversified product offerings.
Read more →VRTXVertex Reports First Quarter 2026 Financial Results
Vertex Pharmaceuticals has reported its financial results for the first quarter of 2026. The article provides an overview of the company's performance, but lacks specific details regarding revenue, expenses, or other financial metrics. Overall, the report seems to be a standard financial update without significant highlights.
Read more →VRTXVertex to Announce First Quarter 2026 Financial Results on May 4th
Vertex Pharmaceuticals is set to announce its first quarter 2026 financial results on May 4, 2026, after market close. A conference call will follow at 4:30 p.m. ET, accessible via phone or webcast. Vertex is known for its innovative therapies for serious diseases and has a strong clinical pipeline.
Read more →VRTXVertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
Vertex Pharmaceuticals has received FDA approval for label extensions of ALYFTREK® and TRIKAFTA®, allowing these treatments to be available for approximately 95% of cystic fibrosis patients in the U.S. The approval specifically targets individuals aged 6 and older with specific CFTR gene variants. This expansion is expected to significantly enhance treatment accessibility for cystic fibrosis.
Read more →VRTXSickle Cell Gene Therapies Casgevy and Lyfgenia Still Lacking Traction 2 Years In
Vertex Pharmaceuticals' Casgevy and Genetix Bio's Lyfgenia, the first gene therapies for sickle cell disease, face challenges in patient uptake two years post-approval. Despite initial excitement and revenue expectations, only a small number of patients have been treated due to complex treatment requirements and concerns about side effects. Both companies are working to improve access and expand their market presence.
Read more →VRTXVertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
Vertex Pharmaceuticals announced its participation in the TD Cowen 46th Annual Health Care Conference, where CEO Reshma Kewalramani will engage in a fireside chat. The event is scheduled for March 3, 2026, at 9:10 a.m. ET. A live webcast will be available on the company's website, with a replay accessible afterward.
Read more →VRTX▲ +5.7%on this newsshared move
All Eyes On Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts
Vertex Pharmaceuticals is progressing with its late-stage study of povetacicept in IgA nephropathy, which has shown no issues so far. The company anticipates critical data in the first half of the year, which will aid in its FDA approval process. However, competition in the IgAN market is intensifying, and sales of its painkiller Journavx have not met expectations.
Read more →VRTXDocument Vertex Reports Fourth Quarter and Full Year 2025 Financial Results - Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024 fourth quarter total revenue of $3.19 billion, a 10% increa
Vertex Pharmaceuticals reported substantial revenue growth in 2025, with total revenue reaching $12.0 billion, marking a 9% increase from the previous year. The company forecasts further revenue growth in 2026, projecting total revenues of $12.95 billion to $13.1 billion, supported by robust performance in cystic fibrosis (CF) therapies and the anticipated launch of non-CF products. Vertex also emphasized the advancement of its clinical pipeline, particularly the ongoing development of povetacicept targeted at immunoglobulin A nephropathy (IgAN). The outcomes from 2025 reinforce Vertex's strong market position and operational execution in delivering innovative treatments.
Read more →VRTXWuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
WuXi Biologics has entered into a license and research service agreement with Vertex Pharmaceuticals for a trispecific T-cell Engager aimed at treating B-cell mediated autoimmune diseases. Vertex will have exclusive global rights to develop this innovative therapy at the preclinical stage. WuXi will receive upfront and milestone payments, highlighting its role in advancing next-generation therapeutic modalities.
Read more →VRTXSatellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
Satellos Bioscience has appointed Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs. Ms. Paone brings significant experience from her previous roles, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals. Her appointment is seen as timely as Satellos advances its clinical studies in Duchenne muscular dystrophy, with potential plans for regulatory approval of SAT-3247.
Read more →VRTXVertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
Vertex Pharmaceuticals will announce its fourth quarter and full year 2025 financial results on February 12, 2026. The announcement will be followed by a conference call and webcast at 4:30 p.m. ET. Vertex is known for its innovative therapies and has a strong pipeline in various serious diseases.
Read more →VRTX5 Clinical Readouts to Watch in H1 2026
The article highlights five key clinical trial readouts anticipated in the first half of 2026, including Novartis's pelacarsen for cardiovascular disease and Vertex's povetacicept for IgA nephropathy. Analysts are particularly focused on these trials due to their potential market impact, especially in the Lp(a) and obesity treatment sectors. The readouts could significantly influence the biopharma landscape and investor sentiment.
Read more →VRTXVertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
Vertex Pharmaceuticals presented new data on CASGEVY at the ASH Annual Meeting, highlighting its efficacy and safety in children aged 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. This marks the first clinical data for this age group. Vertex plans to initiate global regulatory submissions in the first half of 2026.
Read more →VRTXNovartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space
Vertex Pharmaceuticals has acquired Alpine Immune Sciences for $4.9 billion, enhancing its immunology pipeline with the lead asset povetacicept. This dual antagonist is under investigation for autoimmune diseases. Similarly, Novartis is advancing its drug ianalumab for Sjögren’s disease and other conditions. The immunology market's growth is attracting significant investments from major biopharma companies.
Read more →VRTXVertex’s New Products Dim as Analysts Eye Kidney Portfolio
Vertex Pharmaceuticals reported an 11% revenue growth in Q3, meeting expectations. However, new product sales, particularly for Journavx and Casgevy, faced challenges, with Journavx missing revenue targets and Casgevy's sales declining significantly. Analysts remain optimistic about the company's cystic fibrosis products and the upcoming kidney disease drug, povetacicept, which is expected to have significant milestones in 2026.
Read more →VRTXDocument Vertex Reports Third Quarter 2025 Financial Results - Total revenue of $3.08 billion, an 11% increase compared to Q3 2024 - - Refined full year financial guidance total revenue guidance now $11.9 to $12.0 billio
Vertex Pharmaceuticals reported a strong financial performance for Q3 2025, with total revenues of $3.08 billion reflecting an 11% increase compared to the previous year. The company has refined its full year financial guidance, projecting total revenues between $11.9 and $12.0 billion, underpinned by growth in cystic fibrosis therapies and new product launches. The R&D pipeline is progressing well, with five programs in pivotal development and the successful completion of enrollment in a key clinical trial for povetacicept. This robust performance positions Vertex for continued momentum through the end of 2025.
Read more →VRTX5 SMID-Cap Pharmas Poised for M&A Action
A report from Leerink Partners highlights mid-cap biopharma companies, including Vertex Pharma, as potential acquirers of smaller biotechs. Vertex's recent acquisition of Alpine Immune Sciences is noted for its promising pipeline in autoimmune diseases. The report suggests that these companies are well-positioned for M&A activity, despite some facing challenges in their current operations.
Read more →VRTXBioSpaceHonors 40 Under 40 Winners Whose Impact Reflects Industry’s Grit
The inaugural BioSpace 40 Under 40 list honors 40 young professionals in the biopharma sector for their significant contributions and leadership. This cohort includes CEOs, founders, and vice presidents who have demonstrated innovation and commitment to enhancing patient outcomes. The recognition underscores the industry's resilience and the impact of its emerging leaders.
Read more →VRTXVertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact
Vertex Pharmaceuticals and Enlaza Therapeutics have entered a significant partnership to develop innovative therapies for autoimmune diseases, leveraging Enlaza's proprietary War-Lock platform. The agreement includes an upfront payment of $45 million and potential milestone payments exceeding $2 billion. This collaboration represents a strategic move for Vertex as it seeks to enhance treatment options for patients with sickle cell disease and beta thalassemia.
Read more →VRTXFDA In Flux, Pfizer Talks to Trump on MFN, Merck Cuts 6K Jobs, More
The FDA is experiencing leadership changes with George Tidmarsh taking over temporarily. Criticism arises over the rejection of Replimmune's melanoma drug, while Merck announces significant job cuts. Pfizer's CEO is in talks with President Trump regarding drug pricing policies. Additionally, international drugmakers are increasing their presence in China.
Read more →VRTX▼ -20.6%on this newsshared move
Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings
Vertex Pharmaceuticals reported a disappointing Phase II trial failure for VX-993, a non-opioid painkiller, which missed its primary endpoint. Despite this setback, the company announced strong second-quarter earnings, with revenue of $2.96 billion, surpassing estimates. However, concerns arose regarding the FDA's stance on broader approval for Journavx, Vertex's previously successful pain treatment.
Read more →VRTXDocument Vertex Reports Second Quarter 2025 Financial Results - Total revenue of $2.96 billion, a 12% increase compared to Q2 2024 reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12
Vertex Pharmaceuticals reported a strong second quarter for 2025, with total revenues reaching $2.96 billion, a 12% increase from the previous year. This rise was largely attributed to successful launches of new products, including ALYFTREK, JOURNAVX, and CASGEVY. Additionally, the company reaffirmed its financial guidance for the full year, expecting revenue between $11.85 billion and $12 billion. Notably, the company will see a leadership transition with the retirement of CSO David Altshuler set for August 2026.
Read more →VRTXQ2 2025: Biotechs To Watch For This Earnings Season
The Q2 earnings season for biopharma is underway, with notable performances from Johnson & Johnson and Novartis. However, companies like Sarepta and Ultragenyx are facing significant challenges, including patient deaths and regulatory setbacks. Vertex Pharmaceuticals is performing well but has uncertainties regarding new product sales. Analysts remain cautious about the overall industry outlook amidst these mixed results.
Read more →VRTXDocument Vertex Reports First Quarter 2025 Financial Results - Total revenue of $2.77 billion, a 3% increase compared to Q1 2024 raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $1
Vertex Pharmaceuticals reported a strong financial performance for the first quarter of 2025, with total revenue rising to $2.77 billion, aided by product launches and patient demand. The company raised its revenue guidance for the year, reflecting confidence in expanding its cystic fibrosis portfolio and advancing multiple clinical programs. Despite challenges including declining revenues in Russia and a significant impairment charge, the outlook remains positive with pivotal studies advancing. Vertex appears well-positioned for continued growth as it navigates these developments.
Read more →VRTXDocument Vertex Reports Fourth Quarter and Full Year 2024 Financial Results - Full year product revenue of $11.02 billion, a 12% increase compared to full year 2023 - - Company provides full year 2025 total revenue guida
Vertex Pharmaceuticals reported strong financial results for Q4 and full year 2024, with product revenue of $11.02 billion, a 12% increase over 2023. The company also provided guidance for 2025, projecting total revenue of $11.75 billion to $12 billion, underpinned by the anticipated launch of new products including ALYFTREK. However, the acquisition of Alpine Immune Sciences has led to significant R&D expenses, contributing to a net loss for the year. Vertex continues to enhance its portfolio with late-stage clinical programs and FDA approvals, positioning itself for growth in 2025.
Read more →VRTXDocument Vertex Reports Third Quarter 2024 Financial Results - Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 - - Raising full-year product revenue guidance to $10.8 billion to $10.9 billion - - Pre
Vertex Pharmaceuticals reported consolidated financial results for Q3 2024, showcasing a 12% increase in product revenue to $2.77 billion. The company has raised its full-year revenue guidance to $10.8 billion to $10.9 billion while preparing for potential launches of two key therapies. Additionally, Vertex continues the advancement of three programs into Phase 3 development, indicating strong pipeline momentum. However, the increase in R&D and SG&A expenses poses some challenges amid the positive financial outlook.
Read more →VRTXDocument Vertex Reports Second Quarter 2024 Financial Results - Product revenue of $2.65 billion, a 6% increase compared to Q2 2023 - - Company raises full year product revenue guidance to $10.65 to $10.85 billion - - FD
Vertex Pharmaceuticals reported a strong financial performance for Q2 2024, with product revenue increasing by 6% to $2.65 billion. The company raised its full-year revenue guidance to between $10.65 billion and $10.85 billion due to robust growth in its cystic fibrosis (CF) portfolio. Notably, the FDA has accepted new drug applications for vanzacaftor triple and suzetrigine, both under Priority Review. Despite positive revenue growth, the company reported significant net losses attributed to increased R&D expenses following its acquisition of Alpine Immune Sciences.
Read more →VRTXDocument Vertex Reports First Quarter 2024 Financial Results - Product revenue of $2.69 billion, a 13% i ncrease compared to Q1 2023 reiterated full year 2024 financial guidance, including product revenue guidance of $10
Vertex Pharmaceuticals reported a strong financial performance for Q1 2024, achieving product revenue of $2.69 billion, a 13% increase from Q1 2023. The company reiterated its full-year guidance for product revenue between $10.55 to $10.75 billion. Significant regulatory progress includes the NDA submission for vanzacaftor triple in cystic fibrosis and the rolling NDA for suzetrigine for pain management. Additionally, Vertex announced the acquisition of Alpine Immune Sciences, aimed at enhancing its pipeline in IgA nephropathy.
Read more →VRTXDocument Vertex Reports Fourth Quarter and Full Year 2023 Financial Results - Full year product revenue of $9.87 billion, a n 11% i ncrease compared to full year 2022 - - Company provides full year 2024 product revenue g
Vertex Pharmaceuticals announced strong financial results for 2023, reporting a product revenue increase of 11% to $9.87 billion. The company anticipates further growth in 2024, projecting revenues between $10.55 billion and $10.75 billion, driven by ongoing expansion in cystic fibrosis treatments and the launch of CASGEVY. Vertex also outlined advances in its clinical pipeline, including upcoming NDA submissions for VX-548 and Vanzacaftor Triple. The financial results highlight continued progress and investment in research and development operations.
Read more →VRTXDocument Vertex Reports Third Quarter 2023 Financial Results - Product revenue of $2.48 billion, a 6% increase compared to Q3 2022 - - Company raises full year 2023 product revenue guidance to approximately $9.85 billion
Vertex Pharmaceuticals reported a strong financial performance for Q3 2023, with product revenue reaching $2.48 billion, a 6% increase from the previous year. The company has raised its full year revenue guidance to approximately $9.85 billion, driven by the success of TRIKAFTA and ongoing regulatory advancements for other therapies. Upcoming milestones include critical FDA decisions on exa-cel for sickle cell disease and progress in their expanding clinical pipeline. Vertex's financial position remains robust with cash reserves reaching $13.6 billion as of September 30, 2023.
Read more →VRTXDocument Vertex Reports Second Quarter 2023 Financial Results - Product revenue of $2.49 billion, a 14% increase compared to Q2 2022 - - Company raises full year 2023 product revenue guidance to $9.7 to $9.8 billion - -
Vertex Pharmaceuticals reported a strong second quarter for 2023, with product revenue reaching $2.49 billion, reflecting a 14% increase from the same period in 2022. The company has raised its 2023 revenue guidance to $9.7 to $9.8 billion, driven by favorable uptake of its cystic fibrosis treatments. Vertex received FDA acceptance for exa-cel BLAs aimed at treating severe sickle cell disease and transfusion-dependent beta thalassemia, with a priority review set for December 2023. The company continues to advance its clinical pipeline with several anticipated product launches in the near future.
Read more →VRTXDocument Vertex Reports First Quarter 2023 Financial Results - Product revenue of $2.37 billion, a 13% increase compared to Q1 2022 - - Company reiterates full year 2023 financial guidance, including product revenue guid
Vertex Pharmaceuticals reported a strong financial performance for Q1 2023, with product revenue reaching $2.37 billion, a 13% increase compared to the same period in 2022. The company highlighted the approval of TRIKAFTA for children aged 2 to 5, which will enable approximately 900 new patients to access treatment. Vertex reiterated its full-year revenue guidance of $9.55 to $9.7 billion, reflecting strong expectations for continued demand. However, rising expenses in R&D and SG&A led to a decrease in net income compared to the previous year.
Read more →VRTXDocument Vertex Reports Fourth Quarter and Full Year Financial 2022 Results - Full year product revenue of $8.93 billion, an 18% increase compared to full year 2021 - - Full year GAAP and non-GAAP net income increased 42
Vertex Pharmaceuticals reported strong financial results for the fourth quarter and full year 2022, with total product revenue reaching $8.93 billion, an 18% increase over the previous year. The company also reported a significant rise in net income, with increases of 42% for GAAP and 53% for non-GAAP. Looking ahead, Vertex provided optimistic 2023 revenue guidance and emphasized the advancement of its clinical pipeline with several milestones expected. However, increased operational costs and higher tax liabilities were highlighted as potential concerns.
Read more →VRTX▼ -7.5%on this news
Document Vertex Reports Third Quarter 2022 Financial Results - Product revenue of $2.33 billion , an 18% increase compared to Q3 2021 - - Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9
Vertex Reports Third Quarter 2022 Financial Results - Product revenue of $2.33 billion, an 18% increase compared to Q3 2021 - - Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion - - Significant progress in mid- and late-stage pipeline, w
Read more →VRTXDocument Vertex Reports Second Quarter 2022 Financial Results - Product revenues of $2.20 billion , a 22% increase compared to Q2 2021 - - Company raises full year 2022 product revenue guidance to $8.6 to $8.8 billion -
Vertex Reports Second Quarter 2022 Financial Results - Product revenues of $2.20 billion, a 22% increase compared to Q2 2021 - - Company raises full year 2022 product revenue guidance to $8.6 to $8.8 billion - - Recent exa-cel and VX-880 clinical data presentations demonstrate
Read more →VRTXDocument Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes - ViaCyte brings tools, technologies and assets with potential to accelerate development of VX
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes -ViaCyte brings tools, technologies and assets with potential to accelerate development of VX-880, Vertex's fully differentiated, insulin-producing, stem cell de
Read more →VRTXDocument Vertex Reports First Quarter 2022 Financial Results - Product revenues of $2.10 billion, a 22% increase compared to Q1 2021 - - Company reiterates full year 2022 product revenue guidance of $8.4 to $8.6 billion
Vertex Reports First Quarter 2022 Financial Results - Product revenues of $2.10 billion, a 22% increase compared to Q1 2021 - - Company reiterates full year 2022 product revenue guidance of $8.4 to $8.6 billion - - Mid- and late-stage clinical pipeline now spans 6 disease area
Read more →VRTXDocument Vertex Reports Fourth Quarter 2021 and Full Year Financial Results -Full year product revenues of $7.57 billion, a 22% increase compared to full year 2020- -Company provides full year 2022 product revenue guidan
Vertex Reports Fourth Quarter 2021 and Full Year Financial Results -Full year product revenues of $7.57 billion, a 22% increase compared to full year 2020- -Company provides full year 2022 product revenue guidance of $8.4 to $8.6 billion- - Advancing broad clinical pipeline ac
Read more →VRTXDocument Vertex Reports Third-Quarter 2021 Financial Results -Product revenues of $1.98 billion, a 29% increase compared to Q3 2020- -Company raises full-year 2021 guidance for product revenues to $7.4 to $7.5 billion- -
Vertex Reports Third-Quarter 2021 Financial Results -Product revenues of $1.98 billion, a 29% increase compared to Q3 2020- -Company raises full-year 2021 guidance for product revenues to $7.4 to $7.5 billion- -Broad pipeline advancing with recent progress marked by unpreceden
Read more →VRTXDocument Vertex Reports Second-Quarter 2021 Financial Results -Product revenues of $1.79 billion, an 18% increase compared to Q2 2020- - Company raises full-year 2021 guidance for product revenues to $7.2 to $7.4B- - Pha
Vertex Reports Second-Quarter 2021 Financial Results -Product revenues of $1.79 billion, an 18% increase compared to Q2 2020- - Company raises full-year 2021 guidance for product revenues to $7.2 to $7.4B- -Phase 3 study of next-in-class triple combination for CF to begin in t
Read more →VRTXDocument Vertex Reports First-Quarter 2021 Financial Results -Product revenues of $1.72 billion, a 14% increase compared to Q1 2020- - Company advancing clinical programs in six additional diseases beyond cystic fibrosis
Vertex Reports First-Quarter 2021 Financial Results -Product revenues of $1.72 billion, a 14% increase compared to Q1 2020- - Company advancing clinical programs in six additional diseases beyond cystic fibrosis- -Multiple Phase 2 proof-of-concept study results expected in 202
Read more →VRTXDocument Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results -Full-year 2020 GAAP product revenues of $6.20 billion- -Full-year 2020 non-GAAP product revenues of $6.20 billion, a 55% increase compared to f
Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results -Full-year 2020 GAAP product revenues of $6.20 billion- -Full-year 2020 non-GAAP product revenues of $6.20 billion, a 55% increase compared to full-year 2019- -Company provides full-year 2021 product revenue gu
Read more →VRTXDocument Vertex Reports Third-Quarter 2020 Financial Results -Product revenues of $1.54 billion, a 62% increase compared to Q3 2019- -Company raises revenue guidance now expects 2020 product revenues of $6.0 to $6.2 bill
Vertex Reports Third-Quarter 2020 Financial Results -Product revenues of $1.54 billion, a 62% increase compared to Q3 2019- -Company raises revenue guidance now expects 2020 product revenues of $6.0 to $6.2 billion- BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq VRTX) t
Read more →VRTXDocument Vertex Reports Second-Quarter 2020 Financial Results -Product revenues of $1.52 billion, a 62% increase compared to Q2 2019- -Company raises revenue guidance now expects 2020 CF revenues of $5.7 to $5.9 billion-
Vertex Reports Second-Quarter 2020 Financial Results -Product revenues of $1.52 billion, a 62% increase compared to Q2 2019- -Company raises revenue guidance now expects 2020 CF revenues of $5.7 to $5.9 billion- BOSTON -- Vertex Pharmaceuticals Incorporated (Nasdaq VRTX) today
Read more →Competitive Position
How VRTX ranks across every disease it competes inCompetitive Position is a premium feature
See how VRTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial